Back to Search
Start Over
Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children.
- Source :
-
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2010 Oct; Vol. 66 (10), pp. 1017-23. Date of Electronic Publication: 2010 Jun 16. - Publication Year :
- 2010
-
Abstract
- Purpose: The population pharmacokinetics (PK) of lopinavir in tuberculosis (TB)/human immunodeficiency virus (HIV) co-infected South African children taking super-boosted lopinavir (lopinavir/ritonavir ratio 1:1) as part of antiretroviral treatment in the presence of rifampicin were compared with the population PK of lopinavir in HIV-infected South African children taking standard doses of lopinavir/ritonavir (ratio 4:1).<br />Methods: Lopinavir concentrations were measured in 15 TB/HIV-co-infected paediatric patients who were sampled during and after rifampicin-based TB treatment and in 15 HIV-infected children without TB. During TB therapy, the dose of ritonavir was increased to lopinavir/ritonavir 1:1 in order to compensate for the induction of rifampicin. The children received median (interquartile range=IQR) doses of lopinavir 292 mg/m(2) (274, 309) and ritonavir 301 mg/m(2) (286, 309) twice daily. After TB treatment completion the children received standard doses of lopinavir/ritonavir 4:1 (median [IQR] lopinavir dose 289 mg/m(2) [286, 303] twice daily) as did those without TB (median [IQR] lopinavir dose 265 mg/m(2) [249, 289] twice daily).<br />Results: Lopinavir oral clearance (CL/F) was about 30% lower in children without TB than in co-infected children treated with super-boosted lopinavir. However, the predicted lopinavir C(min) was above the recommended minimum therapeutic concentration during TB/HIV co-treatment in the 15 children. Lopinavir CL/F increased linearly during the dosing interval.<br />Conclusions: Increasing the ritonavir dose to achieve a lopinavir/ritonavir ratio of 1:1 when given in combination with rifampicin-based TB treatment did not completely compensate for the enhancement of lopinavir CL/F caused by rifampicin. The time-dependent lopinavir CL/F might be due to a time-dependent recovery from ritonavir inhibition of lopinavir metabolism during the dosing interval.
- Subjects :
- AIDS-Related Opportunistic Infections drug therapy
Anti-HIV Agents administration & dosage
Anti-HIV Agents blood
Child, Preschool
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Therapy, Combination
Female
HIV Infections drug therapy
HIV Protease Inhibitors pharmacokinetics
Humans
Infant
Lopinavir
Male
Pyrimidinones administration & dosage
Pyrimidinones blood
Rifampin administration & dosage
Rifampin blood
Ritonavir administration & dosage
Ritonavir blood
South Africa
Time Factors
Treatment Outcome
Tuberculosis, Pulmonary drug therapy
AIDS-Related Opportunistic Infections metabolism
Anti-HIV Agents pharmacokinetics
HIV Infections metabolism
Pyrimidinones pharmacokinetics
Rifampin pharmacokinetics
Ritonavir pharmacokinetics
Tuberculosis, Pulmonary metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1432-1041
- Volume :
- 66
- Issue :
- 10
- Database :
- MEDLINE
- Journal :
- European journal of clinical pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 20552180
- Full Text :
- https://doi.org/10.1007/s00228-010-0847-9